고위험 환자에서 보코시주맙의 심혈관 효능 및 안전성

Ridker 등(Fri,)이 이 질문을 연구했습니다.

www.synapsesocial.com/papers/69db2ba07a67537a8ba3d12e — DOI: https://doi.org/10.1056/nejmoa1701488

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab· 2017 · 362 citations
2. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials· 2016 · 64 citations
3. The biology and therapeutic targeting of the proprotein convertases· 2012 · 833 citations
4. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events· 2015 · 2,277 citations
5. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy· 2011 · 1,380 citations